Organon & Co.
OGN
Positions held
Your positionsOGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Organon & Co. operates in a competitive healthcare sector with a focus on women's health, which is gaining increased attention and investment.
- Revenue increased by 7% compared to the prior quarter, reaching $1.6 billion.
- Operating margin expanded to 20.7%, indicating improved efficiency.
- The company faces challenges with a high debt-to-equity ratio of 850.2, which may limit financial flexibility.
- Earnings growth has declined by 28.3%, reflecting potential issues in profitability.
- Revenue growth is negative at -2.3%, suggesting difficulties in maintaining sales momentum.
Fundamentals
| Market cap | $3.61B | Enterprise value | $11.03B | Trailing P/E | 17.63 | Forward P/E | 3.80 |
| PEG | — | Price / book | 3.59 | Beta | 1.54 | Dividend yield | 0.58% |
| Revenue growth | -2.3% | Earnings growth | -28.3% | Gross margin | 53.4% | Operating margin | 20.7% |
| Profit margin | 3.4% | ROE | 24.0% | ROA | 5.7% | Debt / equity | 8.50 |
| Current ratio | 1.95 | Free cash flow | $490.75M | Analyst recommendation | none | Mean target | $11.25 |
| 52w high | $13.80 | 52w low | $5.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.5B | $1.5B | $1.6B | $1.6B | — |
| Op margin | 20.7% | 18.2% | 14.4% | 22.3% | 20.5% | — |
| Net income | $108M | $146M | -$205M | $160M | $145M | — |
| Gross margin | 54.4% | 53.6% | 49.2% | 53.5% | 54.8% | — |
| Gross profit | $847M | $783M | $741M | $857M | $874M | — |
| Operating income | $323M | $266M | $217M | $358M | $326M | — |
- Revenue +7% vs prior quarter ($1.6B vs $1.5B).
- Gross margin 54.4% (was 53.6% prior quarter).
- Operating margin expanded to 20.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B | — |
| Op margin | 19.7% | 23.2% | 21.2% | 27.6% | — |
| Net income | $187M | $864M | $1.0B | $917M | — |
| Gross margin | 53.3% | 58.0% | 59.8% | 62.8% | — |
| Gross profit | $3.3B | $3.7B | $3.7B | $3.9B | — |
| Operating income | $1.2B | $1.5B | $1.3B | $1.7B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
2026-09-28 · Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis
2026-09-22 · Why Organon (OGN) Is Getting Attention Today
2026-09-22 · Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device
2026-09-21 · Is Trending Stock Organon & Co. (OGN) a Buy Now?
2026-09-14 · Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review
2026-09-10 · The Surprising Pockmarks On Cooper's Earnings That Caused Its Stock To Dive
2026-09-08 · Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
2026-09-02 · Orogen Royalties Acquires Two Gold Projects in Southwest Utah
Price (daily)
Full chart · RSI · MACD · patterns